BCompany · Healthtech & Bio
Biocross
Biocross is a Spanish biotech company (a 2005 CSIC spin-off) that develops non-invasive, blood-based diagnostic tests for neurodegenerative and related metabolic diseases, centered on its APOE4 biomarker platform (e4Risk®, e4Quant). Its flagship e4Risk® test detects Alzheimer's, cardiovascular disease and Type 2 Diabetes risk from blood plasma with high sensitivity/specificity and is CE-certified (FDA approval pending). It is headquartered in Boecillo (Valladolid).
Founded
2005
Founders
0
News
1
Rounds
0
Investors
3
SectorsBiotechnology, Diagnostics, Neurodegenerative disease, Healthtech
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Profile updated 31 Jul 2026
Founders
No names on record yet.
Global models 5
GGrail
United States · grail.com ↗
Develops a blood-based biomarker test for early, non-invasive disease detection, the same core model as Biocross though focused on cancer rather than neurodegenerative disease.
$1.9BComparable
FFreenome
United States · www.freenome.com ↗
Blood-test biomarker platform for early disease risk detection, mirroring Biocross's non-invasive plasma-biomarker diagnostic approach.
$1.3BComparable
GGuardant Health
United States · guardanthealth.com ↗
Blood-based biomarker diagnostics company that scaled from a VC-backed startup to a public diagnostics leader, same category as Biocross's diagnostic-kit model.
$550MComparable
QQuanterix
United States · www.quanterix.com ↗
Develops ultra-sensitive blood biomarker detection technology (including for Alzheimer's biomarkers), directly comparable to Biocross's blood-based neurodegenerative diagnostics.
$99.5MComparable
CC2N Diagnostics
United States · c2ndiagnostics.com ↗
Closest direct comparable: a blood-based diagnostic test (PrecivityAD) for Alzheimer's disease risk, the same disease focus and business model as Biocross's e4Risk®.
$85MComparable
Investors 3
Funding rounds
No announced rounds on record.
News & media 1
| Published | Article |
|---|---|
| 2026-07-16 |
CDTI Innvierte destina en junio €96M a 7 nuevas coinversiones en capital riesgo y 1 vehículo de inversión ↗
Webcapitalriesgo
|
